20-23 June, 2018 Barcelona
![]() |
![]() |
![]() |
![]() |
1-O | Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors | Funda Meric-Bernstam | ![]() |
![]() |
|||
1-LB | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH) | Mia Chen | ![]() |
![]() |
|||
2-LB | Overall survival results from a phase III trial of trifluridine/tipiracil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS) | Josep Tabernero | ![]() |
![]() |
|||
2-PD | A phase I/II trial of hafnium oxide nanoparticles activated by radiotherapy in hepatocellular carcinoma and liver metastasis | Angelo Cho | ![]() |
![]() |
|||
3-PD | Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumor | Junichi Arita | ![]() |
![]() |
|||
3-P | Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinoma | Jia Wei | ![]() |
![]() |
|||
4-P | MicroRNAs and CDH1 regulation in intestinal-type gastric cancer | chiara molinari | ![]() |
![]() |
|||
5-O | A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer | Yoshinori Kagawa | ![]() |
![]() |
|||
5-P | Retrospective analysis of the frequency of the ALK translocation obtained by immunohistochemistry in gastric adenocarcinomas in a single Costa Rican hospital | Luis Corrales-Rodriguez | ![]() |
![]() |
|||
5-PD | Post-Operative Venous Thromboembolism and Mortality in Patients with Pancreatic Cancer Surgery | Kaushal Majmudar | ![]() |
![]() |
|||
6-PD | Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients | Maud Marques | ![]() |
![]() |
|||
6-P | Personalization of treatment for patients with stomach cancer using molecular genetic markers | Igor Bykov | ![]() |
![]() |
|||
7-O | Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cetiri: Final results and translational analyses of the CRICKET study by GONO | Daniele Rossini | ![]() |
![]() |
|||
8-P | Treatment decisions in adolescents and young adults with gastric cancer in North Estonia Medical Centre from 2007-2016 | Mari Lhmus | ![]() |
![]() |
|||
8-PD | Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting | Mirella Giordano | ![]() |
![]() |
|||
9-PD | Emergence of KRAS mutation may play a major role in the secondary resistance to EGFR blockade | Takeshi Yamada | ![]() |
![]() |
|||
9-P | Epidemiology and overall survival of gastric carcinoma patients (about 210 cases) experience of medical oncology department of CHU Hassan II Fez | hayat erraichi | ![]() |
![]() |
|||
10-P | Berberine inhibits the migration and invasion via AMPK/HNF4a pathway in gastric cancer | Qian Hu | ![]() |
![]() |
|||
10-PD | REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis | Kohei Shitara | ![]() |
![]() |
|||
11-P | Estrone is a marker of the pre-metastatic niche in patients with stomach cancer | Oleg Kit | ![]() |
![]() |
|||
11-PD | SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results | Tomoko Miura | ![]() |
![]() |
|||
11-O | Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC) | Philippe Merle | ![]() |
![]() |
|||
12-PD | Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies | Katarina Gluic | ![]() |
![]() |
|||
12-O | Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study | Katarina Gluic | ![]() |
![]() |
|||
13-PD | Usefulness of colonic tattooing using ICG in patients with colorectal tumors | Jae Ho Park | ![]() |
![]() |
|||
13-O | Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study | Sarah Novack | ![]() |
![]() |
|||
13-P | Redox forms of glutathione mark the aggressiveness of stomach cancer | Irina Goroshinskaya | ![]() |
![]() |
|||
14-P | Diagnostic and therapeutic efficacy of endoscopic enucleation for subepithelial tumors originating from muscularis propria layer | byoung wook bang | ![]() |
![]() |
|||
14-O | Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) An ACCRU Network study | Tanios Bekaii-Saab | ![]() |
![]() |
|||
15-P | Patient derived xenografts from American minority gastric cancer patients | Sam Wang | ![]() |
![]() |
|||
16-PD | Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab | Vilma Pacheco-Barcia | ![]() |
![]() |
|||
16-O | First-line FOLFOX plus panitumumab (pan) followed by 5-FU/LV plus pan or single-agent pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study | Filippo Pietrantonio | ![]() |
![]() |
|||
17-O | FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO | Federica Marmorino | ![]() |
![]() |
|||
17-P | Overall survival of patients with HCC treated with sorafenib versus patients treated with supportive therapy in evidence in Oncology Cabinet of Municipal Hospital of Pascani in session 2013-2018 | Elena-Carmen Bosteanu | ![]() |
![]() |
|||
17-PD | Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC) | Elena Ongaro | ![]() |
![]() |
|||
18-PD | Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based study | Katleen Janssens | ![]() |
![]() |
|||
19-P | Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt | Ahmed Gaballah | ![]() |
![]() |
|||
19-PD | RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles U.S.FDA BB-IND 10091 | Angelica Nazarian | ![]() |
![]() |
|||
20-P | Immunohistochemical study of KRAS, NRAS, BRAF and MSI phenotype in small bowel adenocarcinoma | Vasiliki Michalaki | ![]() |
![]() |
|||
21-P | Molecular profiling of gastrointestinal cancer | PANAGIOTIS PARSONIDIS | ![]() |
![]() |
|||
22-O | Phase II study evaluating trifluridine/tipiracilbevacizumab and capecitabinebevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis | Eric Van Cutsem | ![]() |
![]() |
|||
23-P | Gastrointestinal stromal tumours: Retrospective review of an institution | Helena Magalhaes | ![]() |
![]() |
|||
24-P | Varying distribution of tissue plasminogen activators in gastrointestinal adenocarcinoma | Oleg Kit | ![]() |
![]() |
|||
26-P | Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic head | Elena Frantsiyants | ![]() |
![]() |
|||
27-P | Polymer hydrogels as innovative carriers for anticancer therapy | Magdalena K&281;dzierska | ![]() |
![]() |
|||
28-P | Lipoxin A4 inhibits the paracrine of Nodal in CAFs by suppressing FPRL1/ROS/NF-?B signaling to attenuate invasion and metastasis of gallbladder carcinoma | Yu Shi | ![]() |
![]() |
|||
28-O | Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration | Shintaro Takeuchi | ![]() |
![]() |
|||
30-P | Epidemiological profile and factors associated with mortality among patients with gastrointestinal cancers in a Haitian cancer program | Joseph Jr Bernard | ![]() |
![]() |
|||
31-P | Morbidity trends for ed gastrointestinal cancers in Poland and the costs of treatment | Miroslaw Jarosz | ![]() |
![]() |
|||
33-P | Longitudinal assessment of neutrophil-to-lymphocyte ratio (NLR) from diagnosis until death reveals a biphasic trend in metastatic pancreatic adenocarcinoma patients | Cristina Morelli | ![]() |
![]() |
|||
35-P | Hepatic stellate cells (HSCs) activating HSF1-mediated COMP secretion promote liver metastasis of pancreatic cancer through CD36/AKT/FOXM1 signaling | Liankang Sun | ![]() |
![]() |
|||
36-P | High proliferation is independently associated with disease progression in metastatic pancreatic adenocarcinoma | Sally Temraz | ![]() |
![]() |
|||
40-P | Biochemical and radiological inflammatory markers in oesophageal squamous cell carcinoma treated with radical chemoradiation | Khin Ni Sann | ![]() |
![]() |
|||
41-P | Prognostic impact of C-reactive protein / albumin ratio in locally advanced esophageal cancer | Joana Simes | ![]() |
![]() |
|||
42-P | Definitive chemoradiation in esophageal squamous-cell carcinoma: Carboplatin/paclitaxel versus cisplatin/5-FU | Nuno Tavares | ![]() |
![]() |
|||
43-P | Oncologic outcomes of elderly patients with localized esophageal cancer who underwent curative surgery compared with younger patients | Hyun Ho Choi | ![]() |
![]() |
|||
44-P | Long term survival in advanced esophageal cancer, treated with a French modality of hypofractionated radiotherapy chemotherapy with or without surgery, the experience at the Instituto Nacional de Cancerología, México | Jesus Zamora Moreno | ![]() |
![]() |
|||
45-P | Analysis of global factors associated with survival in esophageal squamous cell carcinoma: Our experience at Ramon y Cajal Hospital | Arantzazu Barquín García | ![]() |
![]() |
|||
48-P | Neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of esophagus: Clinical profile and outcomes from tertiary care cancer centre | Naveen kumar | ![]() |
![]() |
|||
52-P | A phase 3 study of chemotherapy pembrolizumab versus chemotherapy placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 | Ken Kato | ![]() |
![]() |
|||
53-P | Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic factor in gastric cancer | Ahmed Gaballah | ![]() |
![]() |
|||
54-P | Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram | IRENE PECORA | ![]() |
![]() |
|||
55-P | Prolonged overall survival of metastatic gastric cancer patients with BRCA germline mutations | Naama Halpern | ![]() |
![]() |
|||
56-P | Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are independent prognostic factors for overall survival in Hispanic patients with gastric adenocarcinoma | Allan Ramos-Esquivel | ![]() |
![]() |
|||
57-P | Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics | Fabiola Cecchi | ![]() |
![]() |
|||
58-P | The prognostic value of systemic inflammatory factors in patients with HER2-positive metastatic gastric cancer | Nieves Martinez Lago | ![]() |
![]() |
|||
60-P | Comparison of efficacy and safety between redo-endoscopic treatment and surgery for recurrent gastric neoplasms at the scar of prior endoscopic submucosal dissection | Do Hoon Kim | ![]() |
![]() |
|||
63-P | The clinical outcomes and the pathogenetic background of gastric MALT lymphoma in Korea | SANG MIN LEE | ![]() |
![]() |
|||
64-P | Early outcomes of a pilot study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at dose of 130mg/m2 (nacG-SOX130) in stage III gastric cancer | Sayuri Konishi | ![]() |
![]() |
|||
65-P | Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit | Nazim Abbas | ![]() |
![]() |
|||
67-P | Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: A retrospective study | Takatsugu Ogata | ![]() |
![]() |
|||
69-P | Associated factors with overlooked multiple synchronous gastric epithelial neoplasia | Cheol Woong Choi | ![]() |
![]() |
|||
72-P | Is the prognostic effect of etiologies in patients with gastric cardia cancer during a recent decade of Korea? | Suyun Oh | ![]() |
![]() |
|||
73-P | Prognostic factors for gastric cancer after curative gastrectomy | Sarra Karrit | ![]() |
![]() |
|||
74-P | Outcome and prognostic factors of gastric cancer in Tunisia | Sarra Karrit | ![]() |
![]() |
|||
78-P | Management, outcome and prognostic factors of metastatic gastric cancer | Sarra Karrit | ![]() |
![]() |
|||
79-P | Efficacy and safety of nivolumab monotherapy for metastatic gastric cancer | Kohei Akiyoshi | ![]() |
![]() |
|||
80-P | Gastric cancer in young patients under the age of 45 years old: A comparative study with older patients | Sarra Karrit | ![]() |
![]() |
|||
81-P | Early experience on the histopathological response to perioperative docetaxel, oxaliplatin and 5-FU/Sodium levofolinate (FLOT) for patients with resectable gastric adenocarcinoma when compared to cisplatin/5-fluorouracil (CF) | Ana Rolo | ![]() |
![]() |
|||
82-P | Neoadjuvant chemotherapy in gastric cancer | Adda Bounedjar | ![]() |
![]() |
|||
85-P | The impact of the difference in total diameter of metastatic tumor as a prognostic factor for advanced gastric cancer treated with systemic chemotherapy | Yusuke Sasaki | ![]() |
![]() |
|||
86-P | Treatment and testing patterns among patients with HER2 advanced/metastatic gastric, esophageal or gastroesophageal junction (GEJ) adenocarcinoma in the United States | Lisa Hess | ![]() |
![]() |
|||
88-P | Genetic polymorphisms and PG1/PG2 and G17 levels can predict gastric carcinoids in autoimmune atrophic chronic gastritis patients | Renato Cannizzaro | ![]() |
![]() |
|||
89-P | Gastric cancer in Lynch Syndrome: Are precancerous conditions co- risk factors? | Renato Cannizzaro | ![]() |
![]() |
|||
90-P | Ethnic and racial disparities among young patients with noncardia gastric cancer | Matthew Porembka | ![]() |
![]() |
|||
95-P | A randomized clinical trial of apatinib on an intermittent versus continuous dosing schedule in combination with docetaxel for advanced gastric cancer in second-line setting | Xianmeng Wu | ![]() |
![]() |
|||
96-P | A phase 3 study of chemotherapy pembrolizumab vs chemotherapy placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 | Yung-Jue Bang | ![]() |
![]() |
|||
97-P | SIRT therapy with Yttrium-90 resin microspheres in patients with liver cirrhosis Child Pugh B7-9 and unresectable nonmetastatic hepatocellular cancer | Jan Eick | ![]() |
![]() |
|||
98-P | Treatment patterns and costs of care for patients diagnosed with hepatocellular carcinoma (HCC) in the United States (U.S.) | LISA HESS | ![]() |
![]() |
|||
101-P | HEPANOVA: A phase 2 trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma | Hugo Siedlecki | ![]() |
![]() |
|||
102-P | A retrospective review of neutrophil-lymphocyte ratio as a predictive prognostic marker in upper gastrointestinal cancers in three UK hospitals over a nine year period | Nicholas Wreglesworth | ![]() |
![]() |
|||
103-P | The prospective multicenter study of relation between 5-HIAA / substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy | Tetsuhito Muranaka | ![]() |
![]() |
|||
105-P | Clinical outcomes and toxicity of chemoradiation with IMRT for anal cancer | João Fonseca | ![]() |
![]() |
|||
109-P | Detection and management of hyperglycaemia in oncology patients receiving systemic anti-cancer therapy | Laura Morrison | ![]() |
![]() |
|||
110-P | Squamous cell carcinoma of the anal canal and the results of radical treatment with intensity-modulated radiotherapy | Irena Oblak | ![]() |
![]() |
|||
114-P | The prognostic values of tumor characteristics and clinical factors of neuroendocrine tumors: Two centers experience | Banu Ozturk | ![]() |
![]() |
|||
116-P | A long-term analysis of imatinib palliative treatment in gastrointestinal stromal tumors | Isabel Domingues | ![]() |
![]() |
|||
117-P | 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience | Francisca Elena Marti Marti | ![]() |
![]() |
|||
118-P | Chemoradiation for anal canal carcinoma in a comprehensive cancer center: Retrospective cohort study | João Dias | ![]() |
![]() |
|||
119-P | The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302) | Tatsuya Ioka | ![]() |
![]() |
|||
121-P | Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy | Nobumichi Takeuchi | ![]() |
![]() |
|||
123-P | Quality of life by Karnofsky index in patients with gastrointestinal cancer subject to parenteral nutritional therapy | TICIANA MARIA RANGEL DE PAULA PESSOA | ![]() |
![]() |
|||
124-P | De novo malignancies in patients after liver transplantation: A single centre experience | Klara Chmelova | ![]() |
![]() |
|||
125-P | Laparoscopic liver resection for tumors in proximity to major vasculature and the impact of neo-adjuvant systemic therapy | Mathieu DHondt | ![]() |
![]() |
|||
126-P | Impact of revision surgery timing on overall survival in incidentally detected gall bladder cancer: An experience from tertiary care centre of Northern India | Ashutosh Mishra | ![]() |
![]() |
|||
127-P | Impact of lymph node positivity on overall survival in operable gall bladder cancer: An experience from tertiary cancer care centre from Northern India | Ashutosh Mishra | ![]() |
![]() |
|||
128-P | Surgical resection of primary tumor site is prolonged survival in metastatic pancreatic neuroendocrine carcinoma | Tingting Feng | ![]() |
![]() |
|||
129-P | Comparing efficacy of 1-L Peg-Asc with prucalopride versus 2-L Peg-Asc for bowel preparation | Se Hyun Jang | ![]() |
![]() |
|||
130-P | A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies | Jia Wei | ![]() |
![]() |
|||
131-P | Endoscopic detachable auxiliary manipulator in endoscopic submucosal dissection: Animal model studY | Han Jo Jeon | ![]() |
![]() |
|||
132-P | Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabineplacebo versus gemcitabineevofosfamide and identifies candidate targets | Valeriy Domenyuk | ![]() |
![]() |
|||
133-P | The use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and CA 19-9 as prognostic markers for locally advanced pancreatic cancer | Meabh McNulty | ![]() |
![]() |
|||
136-P | Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen | Alessandro Parisi | ![]() |
![]() |
|||
137-P | Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patients | Yasushi Tsuji | ![]() |
![]() |
|||
138-P | Predictive factors for early relapse and survival in resected pancreatic cancer: A single institution experience | Cristina Saavedra | ![]() |
![]() |
|||
139-P | HGCSG 1403: Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer | Satoshi Yuki | ![]() |
![]() |
|||
141-P | PanCO: An open-label, single-arm pilot study of Oncosil in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabinenab-paclitaxel chemotherapies | Thomas Maher | ![]() |
![]() |
|||
142-P | Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer | Maria Drizou | ![]() |
![]() |
|||
143-P | Safety of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients presenting with hyperbilirubinemia secondary to bile duct obstruction | Mitsuhito Sasaki | ![]() |
![]() |
|||
147-P | Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma | Meabh McNulty | ![]() |
![]() |
|||
149-P | Risk factors and epidemiological features of pancreatic cancer in Iran | Akram Pourshams | ![]() |
![]() |
|||
154-P | Real life triplet FIr/FOx chemotherapy in first line metastatic pancreatic ductal adenocarcinoma: Recommended schedule for expected activity and safety and phase II study | Gemma Bruera | ![]() |
![]() |
|||
156-P | Effectiveness and costs of FOLFIRINOX in the treatment of advanced pancreatic cancer in a Portuguese oncology center | Helena Magalhaes | ![]() |
![]() |
|||
157-P | Gemcitabine/nabpaclitaxel efficacy in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma | Vasiliki Michalaki | ![]() |
![]() |
|||
158-P | Correlation of neutrophil lymphocyte ratio, platelet lymphocyte ratio and rate of change of CA 19-9 in predicting outcome for metastatic pancreatic cancer | Adarsh Das | ![]() |
![]() |
|||
159-P | Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine nab-paclitaxel | Vivaldi Caterina | ![]() |
![]() |
|||
160-P | Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice | Gerarrd Carot-Sans | ![]() |
![]() |
|||
161-P | Folfirinox versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study | IN RAE CHO | ![]() |
![]() |
|||
162-P | Second line in pancreatic cancer: Resuming our experience and looking for prognostic factors | Beatriz Antón | ![]() |
![]() |
|||
163-P | Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb | Juraj Prejac | ![]() |
![]() |
|||
164-P | Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival | Vilma Pacheco-Barcia | ![]() |
![]() |
|||
165-P | Clinical outcomes for modified FOLFIRINOX chemotherapy for pancreatic cancer | DANIEL HOLYOAKE | ![]() |
![]() |
|||
168-P | Multiple dose pharmacokinetics of erlotinib when combined with gastric acid reducing agents: A comparison with a physiologically based pharmacokinetic model | Azra Sahmanovic Hrgovcic | ![]() |
![]() |
|||
170-P | Management of patients with unresectable HCC: A simulation-based assessment of medical oncologists practice choices | Emily Meier | ![]() |
![]() |
|||
171-P | Analysis of echoendoscopic punctures of a solid pancreatic lesions in a private institution in Brazil | TICIANA MARIA RANGEL DE PAULA PESSOA | ![]() |
![]() |
|||
172-P | Treatment modalities and prognostic factors of pancreatic cancer: A retrospective study | Imtinane Belaid | ![]() |
![]() |
|||
175-P | Clinical implication of inflammation markers for identifying radiotherapy candidates in inoperable locally advanced pancreas cancer | won kyung cho | ![]() |
![]() |
|||
176-P | Analysis of various clinical and pathological factors affecting survival in patients diagnosed with pancreatic adenocarcinoma: Single institute study | Ahmed Nagy | ![]() |
![]() |
|||
177-P | Epidemiology of pancreatic cancer | Imtinane Belaid | ![]() |
![]() |
|||
180-P | Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An updated analysis | Sally Temraz | ![]() |
![]() |
|||
181-P | Pancreatic head resections: Impact factors, perioperative morbidity, mortality and long-term survival | Bojan ILIJEVEC | ![]() |
![]() |
|||
184-P | CanStem 111P Trial: A Phase 3 Study of Napabucasin (NAPA) Plus Nab-Paclitaxel (nPTX) With Gemcitabine (Gem) in Adult Patients With Metastatic Pancreatic Adenocarcinoma (mPDAC) | Natalie Johnson | ![]() |
![]() |
|||
185-P | PANOVA-3: A phase 3 study of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma | Hugo Siedlecki | ![]() |
![]() |
|||
187-P | Erythrocyte membrane fatty acids as the potential biomarkers for detection of early-stage and progression of colorectal cancer | Margarita Kruchinina | ![]() |
![]() |
|||
189-P | Retinoic acid-induced 2 (RAI2) is a potential tumor suppressor and RAI2 promoter methylation is a poor prognostic marker in colorectal cancer | Wenji Yan | ![]() |
![]() |
|||
191-P | Combined analysis of KRAS, NRAS, BRAF mutations and mismatch repair deficiency testing in Indian patients with metastatic colorectal carcinoma: A single centre experience | TANVI SOOD | ![]() |
![]() |
|||
193-P | RAS status in Algerian metastatic colorectal cancer | Assia Bensalem | ![]() |
![]() |
|||
194-P | Transcribed ultraconserved regions Uc160 and Uc346 in colon cancer progression | Foteinos- Ioannis Dimitrakopoulos | ![]() |
![]() |
|||
195-P | Cost of illness for colorectal cancer at low middle income countries Egypt case | Abdalla Abotaleb | ![]() |
![]() |
|||
197-P | Repurposing ponatinib for the treatment of colorectal cancer | Rodney Luwor | ![]() |
![]() |
|||
199-P | Colorectal cancer screening in Flanders: Advances in personalised screening | Wessel van de Veerdonk | ![]() |
![]() |
|||
201-P | Evaluation of the prognostic value of lymph-node ratio in patients with colon cancer in the oxaliplatin era | Darragh Connell | ![]() |
![]() |
|||
203-P | Survival and prognostic factors of non metastatic rectal adenocarcinoma: Analytic multifactor review of 91 cases | Khadija Darif | ![]() |
![]() |
|||
204-P | Prognostic value of neo-adjuvant treatment in localized rectal cancer about 78 cases | Khadija khadija | ![]() |
![]() |
|||
205-P | Preoperative short course of radiotherapy in ed high risk patients | Monica Caro Gallarin | ![]() |
![]() |
|||
206-P | Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers | Gemma Bruera | ![]() |
![]() |
|||
208-P | Autophagy (A) related proteins evaluation represents an independent survival factor of colorectal cancer (CRC) patients (pts) | Michalis Karamouzis | ![]() |
![]() |
|||
209-P | P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab | Marco Puzzoni | ![]() |
![]() |
|||
210-P | Unexpected discordance in 5-year OS rates between Nx colon cancer patients and those in stages II plus III | Ivan Tonev | ![]() |
![]() |
|||
211-P | Serum angiogenesis associated proteins and clinical outcome in metastatic colorectal cancer patients receiving bevacizumab | Alessandro Passardi | ![]() |
![]() |
|||
212-P | CDX2 immunohistochemistry as a prognostic biomarker for colorectal cancer | Abiola Fatimilehin | ![]() |
![]() |
|||
213-P | An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicities | Fotheringham Susan | ![]() |
![]() |
|||
214-P | Bevacizumab combined with 1st line chemotherapy in elderly patients with metastatic colorectal cancer: Are there good prognostic indicators? | Katarina Gluic | ![]() |
![]() |
|||
216-P | Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method | Michèle Boisdron-Celle | ![]() |
![]() |
|||
217-P | ABCG2 and TOP-1 as predictive biomarkers and targets for therapy in colon cancer | Nils Brnner | ![]() |
![]() |
|||
221-P | Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer: The optimization of pharmacological costs | Jacopo Giuliani | ![]() |
![]() |
|||
223-P | NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologists and surgeons | Satoshi Yuki | ![]() |
![]() |
|||
224-P | Analysis of clinical outcomes of two antiEGFR antibodies, cetuximab and panitumumab, in the 1st line chemotherapy of RAS wild metastatic colorectal cancer, by neutrophil-to-lymphocyte ratio (NLR) kinetics | Dai Manaka | ![]() |
![]() |
|||
225-P | The role of maintenance therapy in the first line treatment of metastatic colorectal cancer | Danila Gridnev | ![]() |
![]() |
|||
226-P | HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment | Michio Nakamura | ![]() |
![]() |
|||
227-P | Analysis of the benefit of the adjuvant chemotherapy in stage II colon cancer according to the presence of classic poor risk factors: Our experience in Ramon y Cajal Hospital | Cristina Saavedra | ![]() |
![]() |
|||
228-P | VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC) | Hideaki Bando | ![]() |
![]() |
|||
230-P | Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors | Renata Biernacka | ![]() |
![]() |
|||
231-P | Clinical significance of microsatellite instability in gender-dependent patients with right-sided colorectal cancer | Ji Hun Choi | ![]() |
![]() |
|||
232-P | Efficacy of adjuvant chemotherapy for elderly patients with colon cancer | Maria Villamayor | ![]() |
![]() |
|||
233-P | Trifluridine/ tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study | Hironaga Satake | ![]() |
![]() |
|||
234-P | Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC) | Mary Smith | ![]() |
![]() |
|||
235-P | Adjuvant chemotherapy for colorectal cancer using oxaliplatin induced irreversible sinusoidal obstruction syndrome | Keisuke Hara | ![]() |
![]() |
|||
236-P | Clinical and pathological features in colorectal cancer associated to Lynch syndrome | OLIVER HIGUERA | ![]() |
![]() |
|||
237-P | Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial | Marco Stellato | ![]() |
![]() |
|||
238-P | Analysis of classical high risk factors in stage III colon cancer: Experience at University Hospital Ramon y Cajal (UHRyC) | Juan José Serrano Domingo | ![]() |
![]() |
|||
239-P | Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant therapy in stage II in colon cancer: Experience in Ramon y Cajal Universitary Hospital | Roberto Martín Huertas | ![]() |
![]() |
|||
240-P | Benefit of the addition of oxaliplatin to 5-FU/leucovorin or capecitabine in adjuvant therapy for stage II/III colorectal cancer in elderly patients: Experience in Ramon y Cajal University Hospital. | Elena Corral de la Fuente | ![]() |
![]() |
|||
242-P | International prospective multi-center clinical trial with adherence to surgical and pathological quality measures: Influence of body mass index (BMI) on outcome in colon cancer | Mladjan Protic | ![]() |
![]() |
|||
243-P | Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy | AKIHITO TSUJI | ![]() |
![]() |
|||
244-P | Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study) | Hironaga Satake | ![]() |
![]() |
|||
246-P | Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients | Mercedes Martinez Villacampa | ![]() |
![]() |
|||
250-P | Capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer: Experience of the oncology department of the university hospital of Oran, Algeria | zoubida Behourah | ![]() |
![]() |
|||
251-P | The prognostic ad predictive value of primary tumor sidedness in the mCRC pts | Banu Ozturk | ![]() |
![]() |
|||
252-P | The evaluation of liver resection for colorectal cancer liver metastases | Masaichi Ogawa | ![]() |
![]() |
|||
253-P | A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study | Masaru Iwata | ![]() |
![]() |
|||
256-P | Treatment efficacy and survival analysis of extremely elderly (80 years of age or older) patients with metastatic colorectal cancer: Single institute retrospective study | Yi-Hsin Liang | ![]() |
![]() |
|||
257-P | Improvement of metastatic colorectal cancer patient survival: a Single institution experience | Elisabetta Fenocchio | ![]() |
![]() |
|||
258-P | HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib | Satoshi Yuki | ![]() |
![]() |
|||
259-P | Variability of current global practice patterns in the management of metastatic colorectal cancer | Krista Marcello | ![]() |
![]() |
|||
260-P | Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrap | Liliana Borsellino | ![]() |
![]() |
|||
261-P | HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index | Satoshi Yuki | ![]() |
![]() |
|||
262-P | Trial-level analysis of early tumor shrinkage and disease control rate as intermediate end points of first-line medical treatment in randomized studies of metastatic colorectal cancer | Giuseppe Colloca | ![]() |
![]() |
|||
264-P | HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction | Satoshi Yuki | ![]() |
![]() |
|||
265-P | Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: A national survey by the Brazilian Group of Gastrointestinal Tumors (GTG) | Renata Peixoto | ![]() |
![]() |
|||
266-P | Retrospective analysis from efficacy with trifluridine-tipiracil (TAS-102) in patients with metastatic colorectal cancer and possible clinical factors associated with a greater benefit: experience at seven hospitals | Jesús Miranda | ![]() |
![]() |
|||
267-P | The prognostic impact of sidedness in RAS wild-type colorectal cancer | Nuno Tavares | ![]() |
![]() |
|||
269-P | Dynamics of the monoclonal antibodies (MABs) treatment rate and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia from 2013 to 2016 | Mikhail Fedyanin | ![]() |
![]() |
|||
270-P | Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC) | Mikhail Fedyanin | ![]() |
![]() |
|||
271-P | Prognostic impact of K-RAS mutational status and primary tumour location in patients undergoing resection for colorectal cancer liver metastases: A METHEPAR analysis (multicentre study in Argentina) | Juan Manuel OConnor | ![]() |
![]() |
|||
272-P | Understanding of metastatic colorectal cancer (mCRC) in the real world: Initial results from a European survey on the unmet needs of patients living with metastatic colorectal cancer | Zorana Maravic | ![]() |
![]() |
|||
273-P | Recruitment for a survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC): Lessons from a European study | Zorana Maravic | ![]() |
![]() |
|||
274-P | The clinical effectiveness and safety of re-induction oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) for the treatment of metastatic colorectal cancer after two lines of chemotherapy (oxaliplatin- and irinotecan-based regimens) | Anastasia Mochalova | ![]() |
![]() |
|||
275-P | Selective internal radiation therapy (SIRT) with yttrium-90 microspheres and peri-procedural FOLFIRI/Irinotecan in pre-treated colorectal liver metastases patients: An analysis of outcomes from a UK Cancer Centre between 2009 and 2017 | Gregory Wilson | ![]() |
![]() |
|||
276-P | Raltitrexed as salvage therapy for metastatic colorectal cancer: A multicenter retrospective study | Ismael Ghanem | ![]() |
![]() |
|||
277-P | Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study) | Carles PERICAY | ![]() |
![]() |
|||
279-P | Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center | Carolina Sales | ![]() |
![]() |
|||
281-P | The impact of primary tumor location in patients with resected colorectal liver metastasis | Vilma Pacheco-Barcia | ![]() |
![]() |
|||
282-P | RAS status in metastatic colorectal cancer: What is the relationship to epidemiological and anatomo-clinical factors? | mariam haffadi | ![]() |
![]() |
|||
283-P | Skin disorders and primary tumor location as a prognostic factor of cetuximab plus chemotherapy in the treatment of advanced colorectal cancer | Takada Shinya | ![]() |
![]() |
|||
284-P | Characteristics of colorectal cancer in the elderly patients about 60 cases | Hanane Fatima Zahra Aliane | ![]() |
![]() |
|||
285-P | Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidence | Emily Meier | ![]() |
![]() |
|||
286-P | Integrating a paradigm shift in the treatment of metastatic colorectal cancer: Effect of online CME on oncologists knowledge and competence | Emily Meier | ![]() |
![]() |
|||
287-P | Treatment based on tumor sidedness in mCRC: Effect of online education on clinician knowledge, competence and confidence | Emily Meier | ![]() |
![]() |
|||
288-P | Causes of death in a cohort of early stage colorectal cancer patients at a regional centre in Australia | Lisi Elizabeth Lim | ![]() |
![]() |
|||
289-P | Prognostic factors for early recurrences following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases | Naveeshini Nair Chandran | ![]() |
![]() |
|||
291-P | The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status | Pina Ziranu | ![]() |
![]() |
|||
292-P | A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer DEREGULATE study | Kiyotaka Kawaguchi | ![]() |
![]() |
|||
293-P | Comorbidities (CM) and potential impact in outcomes of advanced colorectal cancer patients (ACC) in Argentina: EVIREPRO real life program | Andres Jorge Schmilovich | ![]() |
![]() |
|||
294-P | Multicenter phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) | Takeshi Kato | ![]() |
![]() |
|||
295-P | A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer | Owen Murray | ![]() |
![]() |
|||
297-P | CanStem 303C Trial: A Phase 3 Study of Napabucasin (NAPA) in CombinationWith 5-Fluorouracil (5-FU), Leucovorin, and Irinotecan (FOLFIRI) in AdultPatients With Previously Treated Metastatic Colorectal Cancer (mCRC) | Natalie Johnson | ![]() |
![]() |
|||
299-P | Predictive factors of complete pathological response in operated patients with locally advanced rectal cancer after chemoradiotherapy neoadjuvant treatment in Peru | Rodrigo Motta | ![]() |
![]() |
|||
300-P | Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): preliminary results | Paola Simona Ravenda | ![]() |
![]() |
|||
301-P | CRP / albumin ratio can be a predictor of response to neoadjuvant chemoradiotherapy (CRT) in rectal cancer | Tarkan Yetisyigit | ![]() |
![]() |
|||
302-P | Pathological complete response after chemoradiotherapy in locally advanced rectal cancer: Capecitabine or 5-fluorouracil? Which is better? | Xavier Hernández-Yague | ![]() |
![]() |
|||
303-P | Food intake and nutritional status of colorectal cancer patients undergoing radio-chemotherapy in Sardjito hospital | MARTALENA PURBA | ![]() |
![]() |
|||
304-P | Preoperative chemoradiation in locally advanced rectal cancer: A single center experience | Liliana Oliveira | ![]() |
![]() |
|||
305-P | The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer patients who received preoperative chemoradiation and total mesorectal excision | SooYoon Sung | ![]() |
![]() |
|||
307-P | Preoperative predictors for pathologic response and prognosis of rectal cancer after neoadjuvant chemoradiation | Gyu Sang Yoo | ![]() |
![]() |
|||
309-P | Quality improvement in the management of rectal cancer in a large healthcare system in the United States | William Sause | ![]() |
![]() |
|||
311-P | Comparison between the toxicity profile of fluorouracil versus capecitabine concomitant with radiotherapy in patients with non-metastatic rectal cancer | Ahmed Nagy | ![]() |
![]() |
|||
313-P | Nonstandard hypofraction radiotherapy in neoadjuvant chemo-radiation therapy of locally advanced rectal cancer | Abror Abdujapparov | ![]() |
![]() |
|||
314-P | Prone vs supine position in patients with rectal cancer treated with volumetric arc therapy and concurrent chemotherapy | Laura Díaz | ![]() |
![]() |
|||
315-P | The role of palliative re-irradiation in management of rectal cancer | mohan hingorani | ![]() |
![]() |
|||
316-P | Is there any association of dose received by pelvic bone marrow in preoperative radiotherapy in rectal cancer with hematological toxicity of subsequent oxaliplatin-based chemotherapy? | Mateusz Spalek | ![]() |
![]() |
|||
317-P | A single centre experience of in-field recurrence following pre-operative radio(chemo)therapy in patients with rectal cancer | Rajarshi Roy | ![]() |
![]() |
|||
319-P | Long term efficacy results from the phase II CRAB trial: Neoadjuvant bevacizumab, capecitabine and radiotherapy in locally advanced rectal cancer | Vaneja Velenik | ![]() |
![]() |
|||
320-P | Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer | Susan Higgins | ![]() |
![]() |
|||
321-P | Profile of neurotoxicity of oxaliplatin in young versus elderly patients treated for colorectal carcinoma | Hanane Fatima Zahra Aliane | ![]() |
![]() |
|||
322-P | First study in North Africa: Screening colorectal cancer | mazouzi chahira | ![]() |
![]() |
20-23 June, 2018 Barcelona
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|